Research · 9 min read
What an Added Ingredient in a Compounded GLP-1 Actually Is
Compounded semaglutide with B12, tirzepatide with B6, semaglutide with glycine. The approved products contain none of those, and knowing what is on an approved label is the only way to read what an addition means.
Key takeaways
- Glycine, vitamin B12, vitamin B6, carnitine and NAD appear in none of the four approved labels checked.
- An approved label's own ingredient list is short, is named as inactive ingredients, and changes between single-dose and multiple-use presentations.
- An addition is prepared by a compounding pharmacy, and the mixture itself is not reviewed by FDA for safety, effectiveness or quality.
- Whether an addition helps is not established here, and no approved labeling describes the combination.
- FDA reminds telehealth companies not to describe a compounded drug as clinically proven to produce the same result as the approved drug.
- A combination preparation and a single-ingredient one are different purchases, so establish composition before comparing monthly figures.
Answer first: it is something the seller decided to put in
An added ingredient is exactly what the phrase says. A compounding pharmacy prepared the medication with something in the vial that the approved product does not contain. Vitamin B12, vitamin B6, glycine, L-carnitine and NAD all show up in this market as additions of that kind.
None of them appears in the approved labeling of any of these medications. That is the fact worth carrying, and it is checkable rather than rhetorical. What the addition accomplishes is a separate question, and it is one no approved label answers, because no approved label describes the mixture at all.
What follows sets out what an approved vial contains, what the additions are not, and what the difference does to a price comparison. It makes no claim about whether an addition helps you, because nothing in the sources read supports one.
What is actually in an approved vial besides the drug
Every approved label carries a description section that lists what is in the product, and the lists are short. The semaglutide injection labeling names disodium phosphate dihydrate, sodium chloride and water for injection as its inactive ingredients, with hydrochloric acid or sodium hydroxide noted as pH adjusters.
The tirzepatide labelings name sodium chloride, sodium phosphate dibasic heptahydrate and water for injection, again with acid or base for pH. Both tirzepatide labels then say something a reader can use: benzyl alcohol, glycerin and phenol are also inactive ingredients in the multiple-dose vial and the multiple-use pen. The semaglutide labeling follows the same pattern, adding phenol and propylene glycol to the presentation designed for repeated use.
So the list is not fixed even within one approved product. It changes with the presentation, and it changes in a direction anyone can observe: the containers meant to be entered more than once carry ingredients the single-dose ones do not. Each entry is named, and each is given an amount.
The named additions are not on any of those lists
Four approved labels were read in full: the semaglutide injection and tablet labeling, the semaglutide labeling for glycemic control, and both tirzepatide labelings. Glycine appears in none of them. Neither does cyanocobalamin or vitamin B12, neither does pyridoxine or vitamin B6, neither does carnitine, and neither does NAD.
That is not a criticism of any seller. It is the baseline. When a product page says compounded semaglutide with B12, the with is doing real work — it is describing something outside the approved formulation, prepared by a pharmacy rather than approved by a regulator.
It also explains why an added ingredient tends to be listed as a feature rather than as an inactive ingredient. On an approved label an ingredient is disclosed. On a marketing page an addition is frequently sold.
Why an ingredient gets added, in one paragraph
There is a legal frame behind some of these additions, and it is covered in full elsewhere rather than repeated here. Federal law restricts compounding a drug that is essentially a copy of a commercially available one. The statute then carves out a change made for an identified individual patient, where that change produces a significant difference for that patient, as determined by the prescribing practitioner.
FDA has addressed the obvious question directly, using semaglutide combined with vitamin B12 as its own example. The agency's treatment of that example, and the conditions it attaches, are set out in the article on what the shortage decisions changed for compounders. Read that one for the legal mechanics.
The point to carry into a purchase is narrower. An addition can be a genuine clinical decision recorded for one person. It can also be a formulation choice with commercial consequences. Nothing about the ingredient name tells you which, and the seller's page is not the place that settles it.
What an addition does to a price comparison
A monthly figure for a preparation containing extras and a monthly figure for a single-ingredient compounded product are not figures for the same object. Put them in the same column and the comparison silently changes what is being compared.
That cuts both ways. A seller charging more for a combination is not necessarily charging more for the same thing, and a seller charging less for a plain preparation is not necessarily cheaper for less. The honest move is to establish what is in each vial first, then compare.
It is also worth asking whether the added ingredient changes the shipment. A combination preparation is still a compounded vial, and the practical questions that come with any vial apply — what concentration is supplied, how much arrives, and what the instructions say.
What the marketing is not allowed to say
FDA has published a specific list of things it reminds telehealth companies not to claim about compounded GLP-1 drugs. Two of them bear directly on how an enhanced formula gets sold.
One is describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug. Another is claiming a compounded drug has been FDA-approved, or has otherwise been evaluated for safety and effectiveness, when it has not. The agency states plainly that compounded drugs are not reviewed for safety, effectiveness or quality before marketing.
None of that makes a combination preparation improper. It does mean that a page promising a specific outcome from an addition has taken on a burden, and that the absence of such a promise on a careful seller's page is not an oversight.
The questions that turn an ingredient name into a fact
Ask for the full composition of what will be dispensed to you, in writing, and ask which pharmacy prepares it. An ingredient named in a headline is not the same as an ingredient statement.
Ask who decided the addition, and on what basis. A change recorded for you by the prescribing practitioner is a different thing from a house formula every customer receives, and the answer is not usually on the product page.
Ask what the same program charges for a preparation without the addition, if it offers one. And ask who to contact about the finished product once it arrives, since the pharmacy that prepared it is the only party that can speak to what is actually in your vial.
Sources
- WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use — full prescribing informationThe description section's list of inactive ingredients for the single-dose presentation — disodium phosphate dihydrate, sodium chloride and water for injection, with hydrochloric acid or sodium hydroxide noted as pH adjusters — and the separate list for the multiple-use pen, which adds phenol and propylene glycol; and that glycine, cyanocobalamin, vitamin B12, pyridoxine, vitamin B6, carnitine and NAD appear nowhere in the label.
- ZEPBOUND (tirzepatide) injection, for subcutaneous use — full prescribing informationThat the label names sodium chloride, sodium phosphate dibasic heptahydrate and water for injection as inactive ingredients, with hydrochloric acid or sodium hydroxide solution for pH, and states that benzyl alcohol, glycerin and phenol are also inactive ingredients in the multiple-dose vial and single-patient-use pen; and that glycine, cyanocobalamin, vitamin B12, pyridoxine, vitamin B6, carnitine and NAD appear nowhere in the label.
- MOUNJARO (tirzepatide) injection, for subcutaneous use — full prescribing informationThe same inactive ingredient statement and the same additional entries for the multiple-dose vial and single-patient-use pen; and that glycine, cyanocobalamin, vitamin B12, pyridoxine, vitamin B6, carnitine and NAD appear nowhere in the label.
- OZEMPIC (semaglutide) injection, for subcutaneous use — full prescribing informationThe description section's inactive ingredient lists, including disodium phosphate dihydrate, propylene glycol, phenol and water for injections for the pen presentation, and disodium phosphate dihydrate, sodium chloride and water for injection for the single-dose syringe; and that glycine, cyanocobalamin, vitamin B12, pyridoxine, vitamin B6, carnitine and NAD appear nowhere in the label.
- 21 U.S.C. 353a — Pharmacy compoundingThe restriction on compounding regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product, and the definition stating that the term does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner.
- FDA to Telehealth Companies: What to Know When Promoting Compounded DrugsThat the agency reminds telehealth companies not to describe a compounded drug as clinically proven to produce the same result as the FDA-approved drug, and not to claim a compounded drug has been FDA-approved or otherwise evaluated for safety and effectiveness when it has not, stating that compounded drugs are not reviewed by the agency for safety, effectiveness or quality prior to marketing.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossThat compounded drugs are not FDA approved, that the agency does not review them for safety, effectiveness or quality before marketing, and that a consumer with questions about instructions for use or information on the label is directed to contact the compounder who made the drug or the telehealth platform where it was purchased.
- Differences in strength expression on product labels of compounders and conventional manufacturers may lead to dosing errorsThat conventional manufacturers label injectable products with the strength per total volume as the primary and prominent expression on the label, while some compounders label theirs differently, and that FDA has received reports of dosing errors and confusion arising from that difference — the basis for the point that a compounded vial's composition and strength statement have to be read rather than assumed.
Frequently asked questions
Is vitamin B12 in the approved semaglutide products?
No. The four approved labels checked list their inactive ingredients explicitly, and cyanocobalamin does not appear on any of them. The same is true of vitamin B6, glycine, carnitine and NAD across all four labels. An added ingredient of that kind belongs to a compounded preparation, which is prepared by a pharmacy rather than approved by FDA.
Does adding B12 or glycine make the medication work better?
That is not established, and nothing here asserts it in either direction. No approved labeling describes the combination, so there is no labeled account of what it does. A seller claiming a specific result from an addition is making a claim they have to be able to substantiate. FDA has reminded telehealth companies not to describe a compounded drug as clinically proven to produce the same result as an approved one.
Then why do compounders add anything at all?
There is a legal reason available and a commercial one, and the ingredient name does not tell you which applies. Federal law restricts compounding a drug that is essentially a copy of a commercially available product. It carves out a change made for an identified individual patient that produces a significant difference for that patient. The mechanics of that rule, and FDA's own vitamin B12 example, are covered in the article on what the shortage decisions changed for compounders.
The approved vials have phenol and benzyl alcohol in them. Is that the same kind of thing?
It is a different kind of entry. Those are named on the approved label itself, as inactive ingredients, with an amount, and they appear in the presentations designed to be entered more than once. An addition marketed as a feature is not on any approved label at all. The distinction that matters is not whether a vial contains more than one substance, but whether the formulation was reviewed and approved.
How do I compare a combination product against a plain one on price?
Establish the composition of both before you compare the figures, because otherwise the column is comparing two different purchases. Ask each program what is in the vial, at what concentration, and how much arrives per shipment. If a program sells both a combination and a single-ingredient preparation, ask for both prices, which turns the addition into a line you can actually evaluate.
Should I avoid a compounded product with added ingredients?
That is a decision for you and the clinician treating you, and nothing here argues for or against it. What is worth doing first is getting the composition in writing, learning which pharmacy prepared it, and understanding that the mixture itself was not reviewed by FDA for safety, effectiveness or quality. Take those facts into the conversation rather than the product page's description of them.